These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 22981547)

  • 61. The role of renal sympathetic nerves in hypertension: has percutaneous renal denervation refocused attention on their clinical significance?
    Katholi RE; Rocha-Singh KJ
    Prog Cardiovasc Dis; 2009; 52(3):243-8. PubMed ID: 19917336
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Renal denervation in treatment-resistant hypertension: a reappraisal.
    Persu A; Jin Y; Fadl Elmula FE; Renkin J; Høieggen A; Kjeldsen SE; Staessen JA
    Curr Opin Pharmacol; 2015 Apr; 21():48-52. PubMed ID: 25601357
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study.
    Vink EE; Goldschmeding R; Vink A; Weggemans C; Bleijs RL; Blankestijn PJ
    Nephrol Dial Transplant; 2014 Aug; 29(8):1608-10. PubMed ID: 24875664
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente].
    Azpiri-López JR; Assad-Morell JL; Ponce de León-Martínez E; Monreal-Puente R; Dávila-Bortoni A; Vázquez-Díaz LA; Treviño-Frutos RJ; Barrera-Oranday F; Del Angel-Soto JG; Martínez JG; Arellano-Torres M
    Arch Cardiol Mex; 2015; 85(2):154-7. PubMed ID: 25700579
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.
    Young KC; Teeters JC; Benesch CG; Bisognano JD; Illig KA
    J Clin Hypertens (Greenwich); 2009 Oct; 11(10):555-63. PubMed ID: 19817936
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The impact of home nocturnal hemodialysis on end-stage renal disease therapies: a decision analysis.
    McFarlane PA; Bayoumi AM; Pierratos A; Redelmeier DA
    Kidney Int; 2006 Mar; 69(5):798-805. PubMed ID: 16407887
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Percutaneous renal sympathetic denervation: 2013 and beyond.
    Froeschl M; Hadziomerovic A; Ruzicka M
    Can J Cardiol; 2014 Jan; 30(1):64-74. PubMed ID: 24365191
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Denervation (ablation) of nerve terminalis in renal arteries: early results of interventional treatment of arterial hypertension in Poland.
    Bartuś K; Sadowski J; Kapelak B; Zajdel W; Godlewski J; Bartuś S; Bochenek M; Bartuś M; Żmudka K; Sobotka PA
    Kardiol Pol; 2013; 71(2):152-8. PubMed ID: 23575708
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Renal denervation in treatment-resistant hypertension - Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials.
    Kjeldsen SE; Narkiewicz K; Oparil S; Hedner T
    Blood Press; 2014 Jun; 23(3):135-7. PubMed ID: 24842262
    [No Abstract]   [Full Text] [Related]  

  • 71. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
    Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R
    J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550
    [TBL] [Abstract][Full Text] [Related]  

  • 72. InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain.
    Soto M; Sampietro-Colom L; Sagarra J; Brugada-Terradellas J
    Rev Esp Cardiol (Engl Ed); 2016 Jun; 69(6):563-71. PubMed ID: 26907729
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension.
    Cheng HM; Pearson A; Sung SH; Yu WC; Chen CH; Karnon J
    Am J Hypertens; 2015 May; 28(5):604-14. PubMed ID: 25430695
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Efficacy of catheter-based renal denervation in mongrel neurogenic hypertensive dogs].
    Lu CZ; Liu J; Xia DV; Zhao XD; Chen X; Yu X; Xu JQ; Zhang J; Pan L; Liu SY; Wang L
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Jan; 40(1):14-7. PubMed ID: 22490627
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Renal sympathetic denervation for resistant hypertension--an alternate view.
    Das UN
    Med Hypotheses; 2013 Dec; 81(6):1135-6. PubMed ID: 24225122
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effects of renal denervation on insulin resistance.
    Hering D; Esler MD; Schlaich MP
    Expert Rev Cardiovasc Ther; 2012 Nov; 10(11):1381-6. PubMed ID: 23244359
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Renal sympathetic denervation for the treatment of systemic hypertension.
    Burke GM; Sica DA; Frishman WH
    Cardiol Rev; 2012; 20(6):274-8. PubMed ID: 22717655
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
    Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
    Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness of Intensive Blood Pressure Management.
    Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
    JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.